Efficacy of trimebutine therapy in patients with gastroesophageal reflux disease and irritable bowel syndrome
Kountouras, J.; Chatzopoulos, D.; Zavos, C.; Boura, P.; Venizelos, J.; Kalis, A.
Hepato-Gastroenterology 49(43): 193-197
2002
ISSN/ISBN: 0172-6390 PMID: 11941952 Document Number: 1574
Background/Aims: GERD (gastroesophageal reflux disease) occurs in 25-51% of IBS (irritable bowel syndrome) patients. Trimebutine has been effective in some IBS patients by modulating colonic motility. Furthermore, it increases gastric emptying rates, and controls esophageal motility. The aim of this study was to investigate the efficacy of trimebutine therapy in GERD patients with IBS. Methodology: Sixty-nine patients with GERD and IBS underwent upper gastrointestinal endoscopic, histologic and clinical evaluation prior to and 3 months post-treatment. H. pylori presence was determined by histology and CLOtest. Forty patients (Group A) were treated with omeprazole plus trimebutine for 3 months: in 32 H. pylori-positive patients (subgroup A1), a standard triple eradication regimen was introduced. Twenty-nine patients (Group B) were treated with omeprazole for 3 months: in 24 H. pylori-positive patients (subgroup B1), the same eradication therapy was employed. Results: Specialized intestinal metaplasia of the gastroesophageal junction was observed in 20% and in 17.2% of the patients in Groups A and B, respectively. Eradication rates were similar in subgroups A1 (84%) and B1 (83%). In Group A there was a significant improvement in GERD (P=0.003) and IBS symptoms (P<0.0001) as well as esophagitis (P=0.029), when compared with Group B. Conclusions: Trimebutine appears to be effective in patients with GERD and IBS.
Document emailed within 1 workday
